Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.

ABSTRACT:

Abstract

Immunotherapy has become standard of care in the treatment of diffuse large B-cell lymphoma (DLBCL). Changes in immunophenotypes observed at first diagnosis predict therapy outcome but little is known about the resolution of these alterations in remission. Comprehensive characterization of immune changes from fresh, peripheral whole blood revealed a functionally relevant increase of myeloid-derived suppressor cells, reduced naïve T cells, and an increase of activated and terminally differentiated T cells before treatment, which aggravated after therapy. Suggesting causal relation, injection of lymphoma in mice induced similar changes in the murine T cells. Distinct immune imprints were found in those who have survived breast cancer and acute myeloid leukemia. Identified al

SUBMITTER: Pelzl RJ 

PROVIDER: S-EPMC12824679 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature